Get started
Author

Hani Babiker

Observed names: Babiker H, Babiker,Hani, H. Babiker, Hani B. Babiker, Hani M. Babiker
ORCID: 0000-0002-9368-6296
Observed ORCID: 0000-0002-9368-6296
OpenAlex ID: A5130718689
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
2021 · Thomas Powles, Tibor Csőszi, et al. · The Lancet Oncology · 642
A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS
2021 · Maro Ohanian, Martha L. Arellano, et al. · Blood · 16
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial
2026 · Tanios S. Bekaii-Saab, Davide Melisi, et al. · Journal of Clinical Oncology · 9
PDF
Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors
2025 · Himil Mahadevia, Umair Majeed, et al. · JAMA Network Open · 8
PDF
Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm
2026 · Cody Eslinger, Mohamad Sonbol, et al. · Drug Design Development and Therapy · 3
PDF
58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study
2024 · A. Hollebecque, E. Dotan, et al. · European Journal of Cancer · 3
Abstract CT265: A phase 2 multicenter study to evaluate the efficacy of tilsotolimod in combination with nivolumab and ipilimumab for treatment of microsatellite-stable colorectal cancer (ILLUMINATE-206)
2020 · Hani B. Babiker, Heinz-Josef Lenz, et al. · Cancer Research · 3
Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumours: Updated results from ILLUMINATE-101
2019 · H. Babiker, E. Borazanci, et al. · Annals of Oncology · 3
Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis
2026 · Binbin Zheng-Lin, Taro Shibuki, et al. · npj Precision Oncology · 1
Abstract PR013: Navlimetostat (BMS-986504) with or without gemcitabine (GEM) + nab-paclitaxel (nab-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deletion ( MTAP -del) from CA240-0007
2026 · Ben George, Konstantinos Leventakos, et al. · Cancer Research
AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma
2026 · Hari Krishnareddy Rachamala, Naga Malleswara Rao Nakka, et al. · Cell Reports
Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance
2026 · Nayef Abdel-Razeq, Debabrata Mukhopadhyay, et al. · Annals of Pancreatic Cancer
Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer
2026 · Taro Shibuki, Celine Hoyek, et al. · Journal of Gastroenterology
PDF
Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm
2026 · Eslinger,Cody, Sonbol,Mohamad, et al. · Dove Medical Press (Taylor and Francis Group)
A Tumor-Targeted Polymeric-Hydrogel Nanoplatform for Bimodal Triple-Combination Chemotherapy in Pancreatic Ductal Adenocarcinoma
2026 · Debabrata Mukhopadhyay, Naga Malleswara Rao Nakka, et al. · SSRN Electronic Journal
PDF
Various CT-Based Body Composition Parameters Are Independently Associated With Survival in Patients With Pancreatic Ductal Adenocarcinoma
2025 · Koen Wijsman, Derk Klatte, et al. · Pancreatology
TTFields in Locally Advanced Pancreatic Adenocarcinoma
2025 · Shannon Westin, Hani Babiker
Works count: 18
Citation count: 688
H-index: 4
I10-index: 2
Year
Topic
Type